Compare Merck & Co., Inc. (MRK) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs ProShares Ultra Gold ETF — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while ProShares Ultra Gold ETF trades at $46.45 (market cap $716.59M). The key difference: Merck & Co., Inc. is far larger — about 490.2× ProShares Ultra Gold ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while ProShares Ultra Gold ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and ProShares Ultra Gold ETF for 23 Days on average.
| MRK | UGL | |
|---|---|---|
Market Cap | $351.28B | $716.59M |
Volume | 7,969,665 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $156.43 | $85.62 |
52-Week Low | $82.49 | $42.79 |
Typical Hold Time | 98 Days | 23 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
UGL trades at $45.08, up 1.46% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Support is clustered around $44-$45, while resistance sits near $46. Recent news highlights gold's volatility amid shifting Fed rate expectations and Treasury yield pressures, impacting gold-related equities.
The outlook remains cautious due to weak technical momentum and macroeconomic headwinds like rising yields. Upside depends on sustained gold price recovery, but near-term risks from Fed policy and dollar strength suggest limited bullish catalysts. Investors should weigh the stock's sensitivity to commodity cycles against current bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
